Effect of an anti-cd54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice

International Journal of Cancer

Volumn 118, Issue 4, 2006, Pages 932-941

  Wang, Shixuan ^a   Coleman, Elaine J ^b   Pop, Laurentiu M ^b   Brooks, Kimberly J ^b   Vitetta, Ellen S ^b,c   Niederkorn, Jerry Y ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anterior chamber; CD54; Eye; Immunotherapy; Uveal melanoma

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY UV3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HETEROTOPIC TRANSPLANTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SCID MOUSE; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR XENOGRAFT; UVEA MELANOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR ADHESION MOLECULE-1; MELANOMA; MICE; MICE, SCID; NEOPLASM METASTASIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 31544443284     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21289     Document Type: Article

References (43)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-51.
2. Mahoney MC, Burnett WS, Majerovics A, Tanenbaum H. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 1990;97:1143-7.
3. McCarthy JM, Rootman J, Horsman D, White VA. Conjunctival and uveal melanoma in the dysplastic nevus syndrome. Surv Ophthalmol 1993;37:377-86.
4. Niederkorn JY. Immunopathogenesis of intraocular tumors. Prog Retinal Eye Res 1995;14:505-26.
5. Vijayasaradhi S, Houghton AN. Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. Adv Pharmacol 1995;32:343-74.
6. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol 1978;86: 76-80.
7. Augsburger JJ, Mullen D, Kleineidam M. Planned combined I-125 plaque irradiation and indirect ophthalmoscope laser therapy for choroidal malignant melanoma. Ophthalmic Surg 1993;24:76-81.
8. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma [see comments]. Cancer 1993;72:2219-23.
9. COMS. Assessment of metastatic disease status at death in 435 melanoma patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119:670-76.
10. Albert DM. The ocular melanoma story. LIII Edward Jackson Memorial Lecture: Part II. Am J Ophthalmol 1997;123:729-41.
11. Gombos DS, Mieler WF. Therapy of Uveal Melanoma: Methods and Risk Factors Associated with Treatment. In: Albert DM, Polans A, eds. Ocular oncology. New York: Marcel Dekker, Inc., 2003:321-52.
12. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A 1989;86:641-4.
13. Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. Oncology 2000;58:83-8.
14. van der Pol JP, Jager MJ, de Wolff-Rouendaal D, Ringens PJ, Vennegoor C, Ruiter DJ. Heterogeneous expression of melanoma-associated antigens in uveal melanomas. Curr Eye Res 1987;6:757-65.
15. Boyd AW, Wawryk SO, Bums GF, Fecondo JV. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci U S A 1988;85:3095-9.
16. Makgoba MW, Sanders ME, Ginther Luce GE, Gugel EA, Dustin ML, Springer TA, Shaw S. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a Iigand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 1988;18:637-40.
17. Huang YW, Burrows FJ, Vitetta ES, Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. Hybridoma 1993;12:661-75.
18. Huang XQ, Mitchell MS, Liggett PE, Murphree AL, Kan-Mitchell J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol Immunother 1994;38:399-405.
19. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 1989;30:829-34.
20. Albert DM, Ruzzo MA, McLaughlin MA, Robinson NL, Craft JL, Epstein J. Establishment of cell lines of uveal melanoma. Methodology and characteristics. Invest Ophthalmol Vis Sci 1984;25:1284-99.
21. Luyten GP, van der Spek CW, Brand I, Sintnicolaas K, de Waard-Siebinga I, Jager MJ, de Jong PT, Schrier PI, Luider TM. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res 1998;8:11-6.
22. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 2000;165:710-5.
23. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193:661-70.
24. Niederkorn J, Streilein JW, Shadduck JA. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci 1981;20:355-63.
25. Huang YW, Vitetta ES. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Hybridoma 1993;12:621-30.
26. Holmes K FB, Schmid I, and Giorgi JV. Immunofluorescence and cell sorting, 2nd ed., vol. 1. Philadelphia: John Wiley and Sons, 1994.
27. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol 2002;22:13-46.
28. Niederkorn JY. Immunology of uveal melanoma: Immunosuppressive factors and the basis for immunotherapy. In: Albert DMaP, A., ed. Ocular oncology. New York: Marcel Dekker, Inc., 2003:255-68.
29. Niederkorn JY. Immunoregulation of intraocular tumours. Eye 1997;11:249-54.
30. Smallshaw JE, Coleman E, Spiridon C, Vitetta ES. The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3. J Immunother 2004;27:419-24.
31. Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest Ophthalmol Vis Sci 1996;37:1884-91.
32. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993;34:3579-84.
33. Lass JH, Walter EI, Burris TE, Grossniklaus HE, Roat MI, Skelnik DL, Needham L, Singer M, Medof ME. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990;31:1136-48.
34. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci 2000;41: 3492-502.
35. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci 2000;41:4195-202.
36. Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci 1997;38:1277-82.
37. Soler-Rodriguez AM, Uhr JW, Richardson J, Vitetta ES. The toxicity of chemically deglycosylated ricin A-chain in mice. Int J Immunopharmacol 1992;14:281-91.
38. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-89.
39. Ma D, Niederkorn JY. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 1995;86:263-9.
40. Smith ME, Thomas JA. Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue. J Clin Pathol 1990;43:893-900.
41. Cosimi AB, Conti D, Delmonico FL, Preffer FI, Wee SL, Rothlein R, Faanes R, Colvin RB. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990;144:4604-12.
42. Haug CE, Colvin RB, Delmonico FL, Auchincloss H, Jr., Tolkoff-Rubin N, Preffer H, Rothlein R, Norris S, Scharschmidt L, Cosimi AB. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993;55:766-72; discussion 72-3.
43. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.